Clinical Scorecard: Off-the-Shelf CAR T Shows Early Signal in Progressive Multiple Sclerosis
At a Glance
| Category | Detail |
|---|---|
| Condition | Progressive multiple sclerosis (primary progressive, active secondary progressive, or non-active secondary progressive) |
| Key Mechanisms | Azer-cel is an investigational allogeneic CD19-directed CAR T-cell therapy intended to deplete B cells in blood, tissues, and cerebrospinal fluid. |
| Target Population | Adults with progressive MS and disability progression independent of relapse activity during the prior year despite high-efficacy treatment; all study participants had previously received anti-CD20 therapy. |
| Care Setting | Phase I clinical-trial setting; participants received bendamustine lymphodepletion followed by a single azer-cel infusion. |
Key Highlights
- The ongoing Phase I TG-Azercel-101 study included 26 people with progressive MS.
- Peripheral B-cell counts fell below 10 cells per microliter in 25 of 26 participants.
- Among 21 participants with paired cerebrospinal fluid samples, median CD19-positive B-cell events declined by 52.3% at day 10.
- At day 90, disability scores were stable or improved in 16 of 18 evaluable participants; seven of eight assessed at six months remained stable or improved.
- Median follow-up at the September 3 data cutoff was 4.9 months.
Guideline-Based Recommendations
Diagnosis
Management
- In the study, participants received bendamustine lymphodepletion followed by one infusion of 30 million to 500 million CAR T cells.
Monitoring & Follow-up
- The study assessed peripheral B-cell counts, cerebrospinal fluid CD19-positive B-cell events, and Expanded Disability Status Scale scores.
Risks
- No dose-limiting toxicities, grade 3 or higher cytokine release syndrome, grade 2 or higher immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease, or immune effector cell-associated hemophagocytic syndrome were reported.
- Two participants experienced grade 1 or 2 cytokine release syndrome and two developed grade 1 or 2 neurotoxicity.
- Eleven participants experienced grade 3 or higher treatment-emergent adverse events, and four had serious adverse events.
Patient & Prescribing Data
The 26 participants had primary progressive, active secondary progressive, or non-active secondary progressive MS, prior anti-CD20 treatment, and disability progression independent of relapse activity during the previous year despite high-efficacy therapies.
Azer-cel is made from healthy donor T cells for off-the-shelf use. The study evaluated a single infusion after bendamustine lymphodepletion; the reported results are initial findings from an ongoing Phase I study.
Clinical Best Practices
- Interpret the reported disability and safety findings in the context of an ongoing Phase I study with a median follow-up of 4.9 months.
- The article reports investigational study findings and does not provide clinical practice recommendations.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
